Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRR IN IMMUNOTHERAPY

Financiado

Cerrado

COMBINATIONAL USE OF INNATE IMMUNE RECEPTORS FOR CANCER IMMUNOTHERAPY

Cancer is a major scientific and economical challenge that our society has to face and new therapeutic approaches should now be evaluated in order to decrease human and financial cost of this disease. After suffering from many dra... ver más

31/05/2017

CENTRO NACIONAL DE...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-05-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CENTRO NACIONAL DE INVESTIGA...

0.00€ | Lider

Proyectos interesantes

CRITICS

Medical Technol...

Data Science

210K€ Cerrado

PDC2021-121769-C22

Medical Technol...

Data Science

23K€ Cerrado

PDC2021-121769-C21

Medical Technol...

Data Science

127K€ Cerrado

ImmunoChip

Medical Technol...

Data Science

2M€ Cerrado

TIGITtherapy

Medical Technol...

Data Science

150K€ Cerrado

EN_ACTI2NG

Medical Technol...

Data Science

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a major scientific and economical challenge that our society has to face and new therapeutic approaches should now be evaluated in order to decrease human and financial cost of this disease. After suffering from many drawbacks, cancer immunotherapy, which aims at mobilizing the immune system to fight cancer, has recently gained enthusiasm with the completion of several randomized phase III clinical trials. Because of their ability to trigger the innate immune responses, ligands for pattern-recognition receptors (PRRs) have been included in several vaccination protocols. These approaches, however, have unveiled new hurdles. Here we propose to investigate a new approach for cancer immunotherapy in Human, based on the use of PRR ligand-containing tumor cells. We have recently shown that introducing the bacterial protein flagellin into tumor cells stimulates innate immune cells and induces a tumor-specific adaptive immunity. Flagellin recognition by myeloid cells engages three distinct PRRs, but subsequent molecular mechanisms controlling presentation of tumor-associated antigens to T lymphocytes are still poorly defined. In addition, the precise nature of adaptive immune responses that efficiently eradicate tumor cells still needs to be precisely characterized before developing pre-clinical trials in Humans. In this context, flagellin-expressing tumor cells represent a powerful tool to uncover fundamental questions on the control of the adaptive immunity by the innate immune system, which will be necessary for the development of new anti-tumor immunotherapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores